{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T01:10:10Z","timestamp":1742346610002,"version":"3.40.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11136-024-03859-x","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T15:19:24Z","timestamp":1732547964000},"page":"593-594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-reported health status in TTR amyloidosis: which yardstick to use?"],"prefix":"10.1007","volume":"34","author":[{"given":"Vincent","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-3670","authenticated-orcid":false,"given":"Trejeeve","family":"Martyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"3859_CR1","doi-asserted-by":"crossref","unstructured":"Poledniczek, M., Kronberger, C., Willixhofer, R. Health-related quality of life is an independent predictor of outcome in transthyretin amyloid cardiomyopathy: a prospective cohort study. Quality of Life Research. Published online 2024.","DOI":"10.1007\/s11136-024-03723-y"},{"issue":"3","key":"3859_CR2","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/ehf2.14350","volume":"10","author":"P Eldhagen","year":"2023","unstructured":"Eldhagen, P., Lehtonen, J., Gude, E., et al. (2023). Health-related quality of life among transthyretin amyloid cardiomyopathy patients. ESC Heart Fail, 10(3), 1871\u20131882. https:\/\/doi.org\/10.1002\/ehf2.14350","journal-title":"ESC Heart Fail"},{"key":"3859_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.amjcard.2020.10.066","volume":"141","author":"M Hanna","year":"2021","unstructured":"Hanna, M., Damy, T., Grogan, M., et al. (2021). Impact of Tafamidis on Health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). American Journal of Cardiology, 141, 98\u2013105. https:\/\/doi.org\/10.1016\/j.amjcard.2020.10.066","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"3859_CR4","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/ejhf.3190","volume":"26","author":"M Grogan","year":"2024","unstructured":"Grogan, M., Davis, M. K., Crespo-Leiro, M. G., et al. (2024). Effect of long\u2010term tafamidis treatment on health\u2010related quality of life in patients with transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 26(3), 612\u2013615. https:\/\/doi.org\/10.1002\/ejhf.3190","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"3859_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams, D., Tournev, I. L., Taylor, M. S., et al. (2023). Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial. Amyloid, 30(1), 18\u201326. https:\/\/doi.org\/10.1080\/13506129.2022.2091985","journal-title":"Amyloid"},{"issue":"1","key":"3859_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D., Gonzalez-Duarte, A., O\u2019Riordan, W. D., et al. (2018). Patisiran, an RNAi therapeutic, for Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 379(1), 11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"3859_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson, M. D., Waddington-Cruz, M., Berk, J. L., et al. (2018). Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 379(1), 22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"New England Journal of Medicine"},{"key":"3859_CR8","doi-asserted-by":"publisher","unstructured":"Kharoubi, M., B\u00e9zard, M., Broussier, A., et al. (2023). Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis. Front Cardiovasc Med, 10. https:\/\/doi.org\/10.3389\/fcvm.2023.1124660","DOI":"10.3389\/fcvm.2023.1124660"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03859-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-024-03859-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03859-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:41:15Z","timestamp":1742344875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-024-03859-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3859"],"URL":"https:\/\/doi.org\/10.1007\/s11136-024-03859-x","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"type":"print","value":"0962-9343"},{"type":"electronic","value":"1573-2649"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"19 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Hanna has served on advisory boards for Alnylam Pharmaceuticals, Eidos, Ionis, Alexion Pharmaceuticals, and Pfizer. Dr. Martyn serves as an advisor or receives consulting fees from Cleveland Clinic\/American Well Joint Venture, Boehringer Ingelheim\/Eli Lilly, Novo Nordisk, AstraZeneca, Fire1, Prolaio, Pfizer, BridgeBio, has equity in Apricity Robotics and Kilele Health, and receives grant support from Ionis Therapeutics\/AstraZeneca and the Heart Failure Society of America (HFSA). All other authors have no relationships to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}